New Blood Glucose Meter to Provide Advanced Therapy Options for People
with Diabetes Beginning in Canada and Europe
MINNEAPOLIS and TARRYTOWN, N.Y., Aug. 21 /CNW/ -- Medtronic, Inc. (NYSE:
MDT) and Bayer Diabetes Care, a division of Bayer HealthCare LLC and a member
of the Bayer Group (NYSE: BAY), today announced an alliance to distribute and
co-market a new blood glucose meter for Medtronic patients outside the United
States beginning in Canada and Europe. The new meter, based on Bayer's
Contour(R) meter platform, will wirelessly transmit blood glucose test results
directly to MiniMed Paradigm(R) insulin pumps and Guardian(R) REAL-Time
continuous glucose monitoring (CGM) systems. Wireless communications make
data entry easier and more convenient for patients.
As part of the agreement, Bayer Diabetes Care acquires exclusive rights
to Medtronic's proprietary wireless communications protocol in certain markets
outside the United States. The new meter will initially be introduced in
Canada and Germany, followed by a phase one rollout in Europe and in other
countries as agreed upon by the companies. Details of the financial terms of
the agreement are not being disclosed.
"Bayer's strong presence in key global markets such as Canada, Europe,
Latin America and Asia enables Medtronic to reach more diabetes patients with
its advanced technologies," said Sandra Peterson, president of Bayer Diabetes
Care. "This alliance also supports our commitment to helping Medtronic
customers maintain good health through frequent glucose testing."
"Offering this new meter with our insulin pumps and real-time continuous
glucose monitoring systems will improve quality of life and ease of use for
many of our patients," says Chris O'Connell, president of the Diabetes
business at Medtronic. "Our new global alliance allows us to bring trusted,
state-of-the-art solutions to Medtronic patients who strive for the best
possible diabetes management."
Medtronic currently markets the MiniMed Paradigm(R) REAL-Time Insulin
Pump and Continuous Glucose Monitoring System - the world's first insulin pump
with REAL-Time continuous glucose monitoring. Together with CareLink(TM)
Therapy Management Software and wireless glucose meter communication,
Medtronic offers patients an integrated solution for managing their diabetes.
About the Diabetes Business at Medtronic
The Diabetes business at Medtronic (www.medtronicdiabetes.com and
www.medtronic-diabetes.co.uk) is the world leader in diabetes management. The
company's products include insulin pump therapy, continuous glucose monitoring
systems, related disposable products and diabetes management software.
Medtronic, Inc. (www.medtronic.com), headquartered in Minneapolis, is the
global leader in medical technology, alleviating pain, restoring health and
extending life for millions of people around the world.
Bayer HealthCare Diabetes Care
Bayer HealthCare Diabetes Care (www.bayerdiabetes.com) supports customers
in 100 countries. Since the introduction of CLINITEST(R) reagent tablets in
1941, Bayer has led the way in diabetes care product innovation. The company
changed the face of diabetes care in 1969 when it introduced the first
portable blood glucose meter and test strips. Bayer HealthCare further
innovated diabetes management by being the first company to introduce a suite
of blood glucose monitors with No Coding(TM) technology. The BREEZE(R)2 and
CONTOUR(R) blood glucose monitoring systems offer people with diabetes an
unparalleled choice in diabetes management systems. The Arthritis Foundation
in the United States and the Arthritis Society of Canada each granted Ease-of-
Use Commendation to the BREEZE meter, representing the first time a blood
glucose meter has been recognized as easy to use for arthritis sufferers.
In July 2006, Bayer Diabetes Care acquired Metrika Inc., maker and
manufacturer of A1CNow+, a meter-based diabetes monitoring system for
measurement of HbA1c (glycated hemoglobin) an important indicator of long term
blood sugar control. Bayer HealthCare, Diabetes Care global headquarters is
located in Tarrytown, New York, in the United States and operates as part of
Bayer HealthCare LLC, a member of the worldwide Bayer HealthCare group.
About Bayer HealthCare
Bayer HealthCare, a subsidiary of Bayer AG, is one of the world's leading
innovative companies in the healthcare and medical products industry and is
based in Leverkusen, Germany. The company combines the global activities of
the Animal Health, Consumer Care, Diabetes Care and Pharmaceuticals divisions.
The pharmaceuticals business operates under the name Bayer Schering Pharma AG.
Bayer HealthCare's aim is to discover and manufacture products that will
improve human and animal health worldwide.
Medtronic Forward-Looking Statements
Any forward-looking statements are subject to risks and uncertainties
such as those described in Medtronic's Annual Report on Form 10-K for the year
ended April 28, 2006. Actual results may differ materially from anticipated
Bayer Forward-Looking Statements
This news release contains forward-looking statements based on current
assumptions and forecasts made by Bayer Group management. Various known and
unknown risks, uncertainties and other factors could lead to material
differences between the actual future results, financial situation,
development or performance of the company and the estimates given here. These
factors include those discussed in our public reports filed with the Frankfurt
Stock Exchange and with the U.S. Securities and Exchange Commission (including
our Form 20-F). The company assumes no liability whatsoever to update these
forward-looking statements or to conform them to future events or
For further information:
For further information: Yvan Deurbroeck of Medtronic Public Relations,
+41-21-802-7574; or Susan Yarin of Bayer HealthCare Media,
email@example.com, or +1-914-366-1738 Web Site: